Thrombosis Complicating Renal Amyloidosis in Dogs

Slauson, David O.; Gribble, David H.

doi:10.1177/030098587100800406

Cited by 26 publications

(18 citation statements)

References 21 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6,35 The reported prevalence of thromboembolism in dogs with glomerular disease has not been wellestablished, but up to 25.7% of all dogs with glomerular disease and 38.5% of dogs with amyloidosis have thromboemboli noted on necropsy examination. 12,13,36 Decreased AT activity has been reported in dogs with glomerular disease, 13 and case reports have noted circulating lupus-like anticoagulant, 18 platelet hypersensitivity, 15 and generalized evidence of dysregulated hemostasis. 13,14,17 We did not find a significant difference in median platelet count, PT, or APTT between NS and NNGD dogs.…”

Section: Discussionmentioning

confidence: 99%

Comparison of Signalment, Clinicopathologic Findings, Histologic Diagnosis, and Prognosis in Dogs with Glomerular Disease with or without Nephrotic Syndrome

Klosterman

Moore

Galvao

et al. 2011

Veterinary Internal Medicne

View full text Add to dashboard Cite

Background: Nephrotic syndrome (NS) develops most commonly in people with glomerular diseases associated with marked albuminuria. Hypernatremia, hypertension, and progressive renal failure are more prevalent in nephrotic than nonnephrotic human patients.Hypothesis/Objectives: Dogs with NS have higher serum cholesterol, triglyceride, and sodium concentrations, higher urine protein:creatinine ratios (UPC) and systolic blood pressure, and lower serum albumin concentrations than dogs with nonnephrotic glomerular disease (NNGD). NS is associated with membranous glomerulopathy and amyloidosis. Affected dogs are more likely to be azotemic and have shorter survival times.Animals: Two hundred and thirty-four pet dogs (78 NS dogs, 156 NNGD dogs).Methods: Multicenter retrospective case-control study comparing time-matched NS and NNGD dogs. NS was defined as the concurrent presence of hypoalbuminemia, hypercholesterolemia, proteinuria, and extravascular fluid accumulation. Signalment, clinicopathologic variables, histopathologic diagnoses, and survival time were compared between groups.Results: Age, serum albumin, chloride, calcium, phosphate, creatinine, and cholesterol concentrations, and UPC differed significantly between NS and NNGD dogs. Both groups were equally likely to be azotemic at time of diagnosis, and NS was not associated with histologic diagnosis. Median survival was significantly shorter for NS (12.5 days) versus NNGD dogs (104.5 days). When subgrouped based on serum creatinine (o or !1.5 mg/dL), survival of NS versus NNGD dogs was only significantly different in nonazotemic dogs (51 versus 605 days, respectively).Conclusions and Clinical Importance: Presence of NS is associated with poorer prognosis in dogs with nonazotemic glomerular disease. Preventing development of NS is warranted; however, specific interventions were not evaluated in this study.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of Signalment, Clinicopathologic Findings, Histologic Diagnosis, and Prognosis in Dogs with Glomerular Disease with or without Nephrotic Syndrome

Klosterman

Moore

Galvao

et al. 2011

Veterinary Internal Medicne

View full text Add to dashboard Cite

show abstract

“…Occlusion of abdominal veins (Slauson & Gribble 1971;Shahar et al 1998;Laurenson et al 2010;Respess et al 2012) Ischaemic damage to abdominal organs (hepatic, splenic, renal and mesenteric vessels). Acute abdominal pain and signs related to specific organ dysfunction such as acute kidney injury, hepatopathy.…”

Section: Ultrasoundmentioning

confidence: 99%

Abnormal platelet activity in dogs and cats – impact and measurement

Gant

McBride

Humm

2020

J of Small Animal Practice

View full text Add to dashboard Cite

Abnormal platelet activity can either lead to bleeding tendencies or inappropriate thrombus formation and can occur secondarily to a wide variety of disease processes, with a range of clinical consequences and severity. This article will discuss the pathophysiology of platelet function abnormalities and consider a logical diagnostic approach applicable to veterinary practice. Recent advances in platelet function testing will then be discussed, with regards to detection of platelet dysfunction and tailoring of pharmacological manipulation. Although many of these tests are still confined to research or academic institutions, techniques for indirectly assessing platelet function are starting to become more widely available. Although we still require further research to develop guidelines for the use of these tests in clinical decision‐making, the recent advances in this field are an exciting step forward in being able to detect and manage platelet dysfunction in both primary care and referral practice.

show abstract

“…In dogs, PLN is associated with thromboembolic complications and thromboprophylaxis is recommended. However, no established protocols exist for determining which medications are optimal and what type of monitoring should be followed . In veterinary medicine, thromboprophylaxis, using clopidogrel or aspirin, is recommended for all dogs with PLN.…”

Section: Discussionmentioning

confidence: 99%

“…Protein‐losing nephropathy (PLN) in dogs is associated with a hypercoagulable state and thromboembolic risk . The true prevalence of thromboembolic complications in PLN dogs is difficult to ascertain but has been reported to be more than 40% in previous studies .…”

Section: Introductionmentioning

confidence: 99%

Platelet aggregometry testing during aspirin or clopidogrel treatment and measurement of clopidogrel metabolite concentrations in dogs with protein‐losing nephropathy

Shropshire

Johnson

Olver

2020

Veterinary Internal Medicne

View full text Add to dashboard Cite

Background Dogs with protein‐losing nephropathy (PLN) are treated with antiplatelet drugs for thromboprophylaxis but no standardized method exists to measure drug response. It is also unknown if clopidogrel metabolite concentrations [CM] differ between healthy and PLN dogs. Objectives Assess response to aspirin or clopidogrel in PLN dogs using platelet aggregometry (PA) and compare [CM] between healthy and PLN dogs. Animals Six healthy and 14 PLN dogs. Methods Platelet aggregometry using adenosine diphosphate (ADP), arachidonic acid (AA), and saline was performed in healthy dogs at baseline and 1‐week postclopidogrel administration to identify responders or nonresponders. A decrease of ≥60% for ADP or ≥30% for AA at 1 or 3 hours postpill was used to define a responder. At 1 and 3 hours postclopidogrel, [CM] and PA were measured in healthy and PLN dogs. Platelet aggregometry was performed in PLN dogs at baseline, 1, 6, and 12 weeks after clopidogrel or aspirin administration. Results In PLN dogs receiving clopidogrel, PA differed from baseline at all time points for ADP but not for AA at any time point. Most dogs responded at 1 or both time points except for 1 dog that showed no response. For PLN dogs receiving aspirin, no differences from baseline were observed at any time point for either ADP or AA. No differences in [CM] were found at either time point between healthy and PLN dogs. Conclusions and Clinical Importance Platelet aggregometry may represent an objective method to evaluate response to clopidogrel or aspirin treatment and PLN dogs appear to metabolize clopidogrel similarly to healthy dogs.

show abstract

Thrombosis Complicating Renal Amyloidosis in Dogs

Cited by 26 publications

References 21 publications

Comparison of Signalment, Clinicopathologic Findings, Histologic Diagnosis, and Prognosis in Dogs with Glomerular Disease with or without Nephrotic Syndrome

Comparison of Signalment, Clinicopathologic Findings, Histologic Diagnosis, and Prognosis in Dogs with Glomerular Disease with or without Nephrotic Syndrome

Abnormal platelet activity in dogs and cats – impact and measurement

Platelet aggregometry testing during aspirin or clopidogrel treatment and measurement of clopidogrel metabolite concentrations in dogs with protein‐losing nephropathy

Contact Info

Product

Resources

About